No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PCRX240816P20000
- 3.60
- -0.10-2.70%
15min DelayTrading Jul 23 09:31 ET
3.60High3.60Low
3.60Open3.70Pre Close1 Volume13.92K Open Interest20.00Strike Price360.00Turnover177.18%IV17.03%PremiumAug 16, 2024Expiry Date0.24Intrinsic Value100Multiplier24DDays to Expiry3.37Extrinsic Value100Contract SizeAmericanOptions Type-0.4172Delta0.0431Gamma5.34Leverage Ratio-0.0714Theta-0.0072Rho-2.23Eff Leverage0.0200Vega
Intraday
- 5D
- Daily
News
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
Should Value Investors Buy Pacira BioSciences (PCRX) Stock?
J.P. Morgan Maintains Pacira BioSciences(PCRX.US) With Buy Rating
Pacira BioSciences: Medicare and Medicaid Propose New Reimbursement for Exparel
Express News | Pacira BioSciences Announces Centers For Medicare And Medicaid Services Issued Proposed Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Rule For 2025; Proposes New Reimbursement For EXPAREL
Express News | Centers for Medicare and Medicaid Propose New Reimbursement for Exparel in All Outpatient Surgical Environments Beginning January 1, 2025
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more